Research
Hormonal
Resistin acts as a pro-inflammatory mediator that impairs insulin sensitivity through multiple mechanisms, including inhibition of glucose transporter activity, suppression of GLUT4 translocation, and activation of inflammatory pathways like NF-kappaB.
Resistin is a hormone linked to inflammation and insulin resistance. While high levels are associated with metabolic issues, human data is inconsistent. Focus on reducing systemic inflammation through diet and exercise, which may positively influence resistin levels and insulin sensitivity.
ModerateSupportsMEDIUM confidence
According to currently available data, the potential mechanisms of the resistin pro-diabetic effects could involve: (1) inhibition of the intrinsic activity of cell surface glucose transporters... (2) suppression of GLUT4 translocation... (3) induction of inhibitor of insulin signaling, suppressor of cytokine signaling 3... (4) blockade of insulin signal transduction pathways... (5) stimulation of hepatic glucose production... and (6) activation of free fatty acids release from adipose tissue.
Why this rating
The paper reviews multiple studies showing consistent mechanisms in rodents but conflicting results in human observational studies.
Source
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity
Andrea Štofková · Endocrine Regulations · 2010
DOI 10.4149/endo_2010_01_25
narrative_reviewCited 193×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Both resistin and visfatin act as pro-inflammatory mediators that contribute to chronic inflammatory diseases, including rheumatoid arthritis, atherosclerosis, and inflammatory bowel disease, by stimulating cytokine production and immune cell activation.Good
- Visfatin (also known as NAMPT or PBEF) exhibits insulin-mimicking effects in vitro by stimulating glucose uptake and insulin signaling pathways, but its physiological role in humans regarding insulin sensitivity remains controversial and unclear.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →